Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral ketamine for chronic suicidality
ACTRN12618001412224Phase 2Completed
- Sponsor
- Thompson Institute
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in suicidal ideation, sponsored by Thompson Institute. Primary endpoint: Change in suicidality. Started Aug 2018; status: completed.
02
Drugs
ketamine
03
Conditions
suicidal ideation
Beyond the preview
Go deeper on ACTRN12618001412224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001412224.